ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Changes in the Management of Thyroid Cancer

by Thomas R. Collins • March 10, 2019

  • Tweet
  • Email
Print-Friendly Version

Changes are stirring in the management of thyroid cancers, from molecular testing to surveillance in select cases, and from nerve monitoring to the choice between total thyroidectomy over hemi-thyroidectomy for certain tumors. An expert panel reviewed the main points in a session at the Triological Society Combined Sections Meeting, held in Coronado, Calif., January 24–26, 2019.

You Might Also Like

  • Management Issues in Recurrent and Metastatic Thyroid Cancer
  • Total or Hemithyroidectomy for Papillary Thyroid Microcarcinoma?
  • Active Surveillance of Papillary Thyroid Cancer Safe, Effective Alternative to Surgery in Some Patients
  • Changes in Thyroid Cancer Incidence Post-2009 ATA Guidelines
Explore This Issue
March 2019

Robert Witt, MD, professor of otolaryngology–head and neck surgery at Thomas Jefferson University in Philadelphia, said molecular tests are becoming increasingly important in the diagnosis and exclusion of thyroid cancer. “We are, I believe, at the beginning of a renaissance in the management of thyroid disease,” he said. “And I think it’s spearheaded by molecular testing.”

There are four main commercial testing options: the Genetic Sequencing Classifier; ThyroSeqv3; ThyGenX & ThyraMIR; and RosettaGX Reveal. The value of the testing on indeterminate thyroid nodules (Bethesda Grade 3 or 4) stems from their ability either to improve accuracy of ruling in thyroid cancer, with positive predictive values that can cut down on the number of completion thyroidectomies, or to rule out thyroid cancer, with negative predictive values that can reduce unnecessary surgery on indeterminate thyroid nodules that would ultimately be found to be benign if they underwent operation.

Positive predictive values (PPV) with the available tests stand at 47% to 82%. Negative predictive values (NPV) are much better, ranging from 91% to 99%. “This is the real stronghold of molecular testing today,” Dr. Witt said, referring to NPV. “I think the positive predictive values are a little bit wanting.” But he added that a lot of nodules labeled suspicious, but not certain for cancer by these tests, and treated with diagnostic lobectomy, will be low-grade, such as follicular variant papillary thyroid cancer, and many don’t require completion thyroidectomy.

“I’m expecting in the next year—or two or three—that the PPV on all of these tests is going to bump up with advancements in mutation identifications and microRNA analysis,” he said.

Ultimately, on the question of whether molecular testing for indeterminate thyroid nodules improves specificity analysis and positive predictive value, the answer, Dr. Witt said, is “maybe.” For BRAF or RET/PTC mutations, the answer is yes, but discovery of other mutations might not eliminate completion thyroidectomy if a diagnostic lobectomy was performed. But, he added, completion thyroidectomy, depending on clinical evaluation and ultrasound, is not mandated by American Thyroid Association guidelines for differentiated thyroid cancers smaller than 4 cm.

Pages: 1 2 3 4 | Single Page

Filed Under: Features, Home Slider Tagged With: Clinical Guidelines, thyroid cancer, treatment, Triological Society Combined Sections Meeting 2019Issue: March 2019

You Might Also Like:

  • Management Issues in Recurrent and Metastatic Thyroid Cancer
  • Total or Hemithyroidectomy for Papillary Thyroid Microcarcinoma?
  • Active Surveillance of Papillary Thyroid Cancer Safe, Effective Alternative to Surgery in Some Patients
  • Changes in Thyroid Cancer Incidence Post-2009 ATA Guidelines

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.